Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives

Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives
Adding Erleada (apalutamide), Janssen's next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, a Phase 3 trial shows. The findings — which supported Janssen's application to the U.S. Food and Drug Administration requesting Erleada's approval for this patient population — were recently revealed during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The presentation was titled “First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT),” and findings were simultaneously published in The New England Journal of Medicine. ADT is one of the mainstays of prostate cancer treatment. It works by reducing the amount of androgens — the so-called "male hormones," including testosterone — in the body. Because androgens drive the growth of some prostate cancers (the "castration-sensitive" ones, defined by their responsiveness to ADT), this lowering of hormone levels can slow cancer growth. Erleada works by binding to the androgen receptor, blocking
Subscribe or to access all post and page content.

Tagged , , , , .

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

Leave a Comment

Your email address will not be published. Required fields are marked *